Close Menu

George Church, David Walt, Kevin Chen

Jul 24, 2018

Molecular diagnostics firm NuProbe Global has formed a scientific advisory board and appointed a new member to its board of directors. The firm has named George Church and David Walt as members of the scientific board. Church and Walt are currently professors of genetics and pathology, respectively, at Harvard Medical School. The firm has also appointed Kevin Chen, founding partner at Biotrack Capital, as a member of the board of directors. Chen has previously led investment in healthcare companies including Beijing Genomics Institute (BGI), Betta Pharma, and Yuwell Medical. 

More Like This

Jan 24, 2020

Guardant Health: Kumud Kalia

Guardant Health has appointed Kumud Kalia as its new chief information officer. In the role, he will lead the company's enterprise applications, information technology, and security teams.

Kalia was most recently chief information and technology officer at Cylance, and previously served the same role at Akamai Technologies. He received Computerworld's "best in class" recognition among its 100 premier information technology leaders and has led teams that have won CIO100, CTO25, and other prestigious industry awards. He holds an honors degree in electronic engineering from Bangor University, is a chartered engineer, and is a fellow of both the Institution of Engineering and Technology and the British Computer Society.

Jan 23, 2020

Agilent Technologies: Mark Doak, Padriag McDonnell

Agilent Technologies said this week that Mark Doak will retire as senior VP of the firm and president of Agilent CrossLab Group, effective May 1, 2020. Agilent has named Padraig McDonnell, currently VP and general manager of the firm's chemistries and supplies division, to succeed Doak. McDonnell has served in various roles at Agilent for 22 years.  

Jan 21, 2020

Zymergen: Jay Flatley

Jay Flatley has joined the board of directors of Zymergen, serving as lead independent director. He is the chairman of the board of Illumina. From 1999 until 2016, Flatley was the CEO of Illumina, and until the end of 2019, he was the company's executive chairman.

Jan 21, 2020

GenMark Diagnostics: James McNally

GenMark Diagnostics said that on Jan. 9, it notified James McNally, its senior vice president of marketing and business development, that his employment with the firm would cease on Jan. 10.

In a filing with the US Securities and Exchange Commission, GenMark also said that on Jan. 14, it entered into a separation agreement and general release with McNally. In accordance with the agreement, McNally is entitled to benefits, including a gross lump sum payment equal to six months of his base salary in effect as of the separation date; an amount equal to McNally’s target bonus percentage under the firm's 2019 bonus plan multiplied by a percentage tied to the achievement of the company-level performance targets under the plan; and an aggregate of 35,702 restricted stock units held by McNally as of the separation date.

Jan 21, 2020

Qlucore: Johan Thiel and Boel Sundvall

Qlucore has named Johan Thiel and Boel Sundvall to its board of directors. Thiel is a longtime entrepreneur who served for six years as CEO of MIPS, a Swedish company known for making a "brain protection system" for bicycling and snowboarding helmets that reduces rotational forces that often lead to concussions. Sundvall comes from a background in corporate finance, investor relations, and communications, including with MIPS.  

Jan 15, 2020

Tempus: Ari Caroline, Iker Huerga

Tempus has hired Ari Caroline as senior VP of health strategy and Iker Huerga as VP of data engineering and strategy. Both founded healthcare artificial intelligence firm Da'At AI, an early-stage startup that Tempus recently acquired the entire team of. Prior to launching Da'At, Caroline was chief analytics officer at Memorial Sloan-Kettering Cancer Center in New York, while Huerga served as director of engineering and applied machine learning for MSK.

Jan 15, 2020

Illumina: Jay Flatley

Jay Flatley has become chairman of the board of directors at Illumina. Until the end of 2019, he was executive chairman, and from 1999 until mid-2016, he was Illumina's CEO. Previously, he was president and CEO of Molecular Dynamics, now part of GE Healthcare. Before that, he was VP of engineering and strategic planning at Plexus Computers, executive VP at Manning Technologies, and held various positions at Spectra Physics.

Jan 14, 2020

Myriad Genetics: Thomas Slavin

Thomas Slavin will be senior VP of medical affairs at Myriad Genetics' oncology division. Starting March 2, he will report to Nicole Lambert, president of Myriad Oncology, and be in charge of Myriad's portfolio of molecular and companion diagnostic products and services for oncology. Slavin is board certified in clincial genetics, medical diagnostics, and pediatrics, and most recently was an assistant professor in City of Hope National Medical Center's medical oncology & therapeutics research and population sciences division. 

Jan 13, 2020

T2 Biosystems: Tony Pare

T2 Biosystems has promoted Tony Pare to the newly created position of chief commercial officer, effective immediately. Pare previously served as vice president and general manager of T2 Biosystems' international business. Prior to that, he held senior business development positions at Haemonetics and Hemanext.

Jan 13, 2020

Spartan Bioscience: Dirk Sibbing; Gilles Montalescot; Marco Valgimigli; Davide Capodanno

Spartan Bioscience has establishd a scientific advisory board in Europe. The members are Dirk Sibbing, an inverventional cardiologist and professor of cardiology at Ludwig-Miximilians University in Munich; Gilles Montalescot, a professor of cardiology at the University of Paris VI, and director of the cardiac care unit at Pitié-Salpêtrière Hospital, Paris; Marco Valgimigli, associate professor of cardiology and senior interventional cardiology at Inselspital Universitätsspital in Bern, Switzerland; and Davide Capodanno, associate professor of cardiology at the University of Catania, Italy, and interventional cardiologist, Azienda ""Policlinico-Vittorio Emanuele" in Catania. The company added that a North American team will be announced in March at the American College of Cardiology conference. 

 
Jan 13, 2020

Foundation Medicine: Ritesh Khullar

Ritesh (Tesh) Khullar has been appointed as chief commercial officer of Foundation Medicine, effective Jan. 20. He joins the Roche subsidiary from Flatiron Health, where he was responsible for leading and scaling provider service offerings. Prior to that, he was the national VP and general manager of sales and account management at McKesson Specialty Health. He also held various roles at Oncology Therapeutics Network. Khullar holds an MBA from the University of San Francisco and a BA in history with a minor in computer science and engineering, political science, and law and society from the University of California, San Diego.

Jan 13, 2020

Twist Bioscience: Patrick Weiss, Bill Banyai

Twist Bioscience has promoted Patrick Weiss to chief operating officer from senior VP of R&D and general manager of data storage. It has appointed Bill Banyai as senior VP of advanced development and general manager of data storage.

Before helping to build Twist's operational infrastructure, Weiss served as President and CEO of Operon Biotechnologies. He also founded Xeragon, an RNA synthesis and bioinformatics firm acquired by Qiagen in 2002. He holds a master's degree in chemistry from the Swiss Federal Institute of Technology and is an author on several patents.

Banyai is a cofounder and director of the company and will maintain his board seat. He led the integration of Genome Compiler, which Twist acquired in 2016 and has overseen facilities expansions. Banyai previously served as VP of hardware at Complete Genomics. He holds a doctorate in optical science from the University of Arizona.

Jan 10, 2020

Oxford Nanopore Technologies: John O'Higgins, Clive Brown

John O'Higgins and Clive Brown have joined the board of directors of Oxford Nanopore Technologies, the company said this week. According to a regulatory filing, the appointments were made last September. Brown is the company's chief technology officer. O'Higgins, who joined the board as a non-executive director, is the former CEO of Spectris, an instrumentation and controls company. He holds non-executive roles at several other companies and is a member of the corporate advisory board of Great Ormond Street Hospital Charity in the UK.

Jan 10, 2020

Transplant Genomics: John Holman

Mansfield, Massachusetts-based Transplant Genomics has appointed John Holman as VP of Medical Affairs. He will replace Roy First, who will continue working as senior clinical advisor. Prior to TGI, Holman served as VP of Immunology and Translational Medicine at Quark Pharmaceuticals. He has also served as VP of clinical research at Myriad Genetics for three years. Prior to Myriad, Holman served as executive medical director as Astellas. 

Jan 09, 2020

Bio-Rad Laboratories: Dara Grantham Wright

Bio-Rad Laboratories has appointed Dara Grantham Wright as executive vice president of its clinical diagnostics group. She will replace John Hertia, who retired Dec. 31, 2019. Grantham Wright most recently served as VP and general manager of the protein and cell analysis biosciences division at Thermo Fisher Scientific. She has also held senior positions at Affymetrix, Boreal Genomics, and Becton Dickinson.

Rady Children's Institute for Genomic Medicine and Deloitte are looking into the use of drones to transport samples for testing. 

Direct-to-consumer genetic testing firm 23andMe is laying off about 100 people.

Researchers from Northwestern University examined dust for antibiotic-resistance genes, New Scientist reports. 

In Science this week: researchers present a computational method for predicting cellular differentiation state from single-cell RNA sequencing data, and more.